Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan in PAH
NCT00091598Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2004
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of ambrisentan in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Gilead Sciences. Primary endpoint: Change from baseline in six minute walk distance at 12 weeks. Started Jan 2004; status: completed.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00091598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091598.